266 related articles for article (PubMed ID: 27877078)
1. Activation of the CXCL16/CXCR6 Pathway by Inflammation Contributes to Atherosclerosis in Patients with End-stage Renal Disease.
Hu ZB; Chen Y; Gong YX; Gao M; Zhang Y; Wang GH; Tang RN; Liu H; Liu BC; Ma KL
Int J Med Sci; 2016; 13(11):858-867. PubMed ID: 27877078
[No Abstract] [Full Text] [Related]
2. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.
Gutwein P; Schramme A; Sinke N; Abdel-Bakky MS; Voss B; Obermüller N; Doberstein K; Koziolek M; Fritzsche F; Johannsen M; Jung K; Schaider H; Altevogt P; Ludwig A; Pfeilschifter J; Kristiansen G
Eur J Cancer; 2009 Feb; 45(3):478-89. PubMed ID: 19070478
[TBL] [Abstract][Full Text] [Related]
3. Associations of CXCL16/CXCR6 with carotid atherosclerosis in patients with metabolic syndrome.
Lv Y; Hou X; Ti Y; Bu P
Clin Nutr; 2013 Oct; 32(5):849-54. PubMed ID: 23398954
[TBL] [Abstract][Full Text] [Related]
4. The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation.
Meijer J; Ogink J; Kreike B; Nuyten D; de Visser KE; Roos E
Cancer Res; 2008 Jun; 68(12):4701-8. PubMed ID: 18559516
[TBL] [Abstract][Full Text] [Related]
5. Activation of mTOR contributes to foam cell formation in the radial arteries of patients with end-stage renal disease.
Ma KL; Liu J; Gao M; Wang CX; Ni J; Zhang Y; Zhang XL; Liu H; Wang YL; Liu BC
Clin Nephrol; 2014 Jun; 81(6):396-404. PubMed ID: 24755105
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of CXCL16/CXCR6 expression in patients with prostate cancer.
Ha HK; Lee W; Park HJ; Lee SD; Lee JZ; Chung MK
Mol Med Rep; 2011; 4(3):419-24. PubMed ID: 21468586
[TBL] [Abstract][Full Text] [Related]
7. The chemokine, CXCL16, and its receptor, CXCR6, are constitutively expressed in human annulus fibrosus and expression of CXCL16 is up-regulated by exposure to IL-1ß in vitro.
Gruber HE; Marrero E; Ingram JA; Hoelscher GL; Hanley EN
Biotech Histochem; 2017; 92(1):7-14. PubMed ID: 27869573
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein(a) accelerated the progression of atherosclerosis in patients with end-stage renal disease.
Ma KL; Gong TK; Hu ZB; Zhang Y; Wang GH; Liu L; Chen PP; Lu J; Lu CC; Liu BC
BMC Nephrol; 2018 Aug; 19(1):192. PubMed ID: 30071823
[TBL] [Abstract][Full Text] [Related]
9. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.
Lu Y; Wang J; Xu Y; Koch AE; Cai Z; Chen X; Galson DL; Taichman RS; Zhang J
Mol Cancer Res; 2008 Apr; 6(4):546-54. PubMed ID: 18344492
[TBL] [Abstract][Full Text] [Related]
10. [The effects of failure of low density lipoprotein receptor expression induced by inflammation on radial artery foam cell formation in patients with end-stage renal disease].
Ma KL; Liu J; Gao M; Ni J; Zhang Y; Zhang XL; Liu H; Huang HQ; Chen L; Wang YL; Liu BC
Zhonghua Nei Ke Za Zhi; 2013 Jun; 52(6):464-8. PubMed ID: 24059991
[TBL] [Abstract][Full Text] [Related]
11. CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering.
Singh R; Kapur N; Mir H; Singh N; Lillard JW; Singh S
Oncotarget; 2016 Feb; 7(6):7343-53. PubMed ID: 26799186
[TBL] [Abstract][Full Text] [Related]
12. The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers.
Darash-Yahana M; Gillespie JW; Hewitt SM; Chen YY; Maeda S; Stein I; Singh SP; Bedolla RB; Peled A; Troyer DA; Pikarsky E; Karin M; Farber JM
PLoS One; 2009 Aug; 4(8):e6695. PubMed ID: 19690611
[TBL] [Abstract][Full Text] [Related]
13. Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma.
Guo L; Cui ZM; Zhang J; Huang Y
Chin J Cancer; 2011 May; 30(5):336-43. PubMed ID: 21527066
[TBL] [Abstract][Full Text] [Related]
14. Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin.
Scholz F; Schulte A; Adamski F; Hundhausen C; Mittag J; Schwarz A; Kruse ML; Proksch E; Ludwig A
J Invest Dermatol; 2007 Jun; 127(6):1444-55. PubMed ID: 17363916
[TBL] [Abstract][Full Text] [Related]
15. CXCL16/CXCR6 chemokine signaling mediates breast cancer progression by pERK1/2-dependent mechanisms.
Xiao G; Wang X; Wang J; Zu L; Cheng G; Hao M; Sun X; Xue Y; Lu J; Wang J
Oncotarget; 2015 Jun; 6(16):14165-78. PubMed ID: 25909173
[TBL] [Abstract][Full Text] [Related]
16. Involvement of Escherichia coli in pathogenesis of xanthogranulomatous cholecystitis with scavenger receptor class A and CXCL16-CXCR6 interaction.
Sawada S; Harada K; Isse K; Sato Y; Sasaki M; Kaizaki Y; Nakanuma Y
Pathol Int; 2007 Oct; 57(10):652-63. PubMed ID: 17803654
[TBL] [Abstract][Full Text] [Related]
17. Human P2X7 receptor activation induces the rapid shedding of CXCL16.
Pupovac A; Foster CM; Sluyter R
Biochem Biophys Res Commun; 2013 Mar; 432(4):626-31. PubMed ID: 23428418
[TBL] [Abstract][Full Text] [Related]
18. Distribution and kinetics of SR-PSOX/CXCL16 and CXCR6 expression on human dendritic cell subsets and CD4+ T cells.
Tabata S; Kadowaki N; Kitawaki T; Shimaoka T; Yonehara S; Yoshie O; Uchiyama T
J Leukoc Biol; 2005 May; 77(5):777-86. PubMed ID: 15703197
[TBL] [Abstract][Full Text] [Related]
19. Atherogenic lipids induce high-density lipoprotein uptake and cholesterol efflux in human macrophages by up-regulating transmembrane chemokine CXCL16 without engaging CXCL16-dependent cell adhesion.
Barlic J; Zhu W; Murphy PM
J Immunol; 2009 Jun; 182(12):7928-36. PubMed ID: 19494317
[TBL] [Abstract][Full Text] [Related]
20. The CXCL16 A181V mutation selectively inhibits monocyte adhesion to CXCR6 but is not associated with human coronary heart disease.
Petit SJ; Wise EL; Chambers JC; Sehmi J; Chayen NE; Kooner JS; Pease JE
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):914-20. PubMed ID: 21233446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
